<DOC>
	<DOCNO>NCT00536614</DOCNO>
	<brief_summary>This multicenter , open-label , randomize , phase II trial patient locally advance metastatic pancreatic cancer . Primary objective : objective response rate . Secondary objective : safety , time disease progression , median duration response , time treatment failure , overall survival time , correlation bio-pathological characterization ( EGFR , akt , MAPks ) objective response survival</brief_summary>
	<brief_title>Gemcitabine/Cisplatin +/-Cetuximab Patients With Locally Advanced Metastatic EGFR-Positive Pancreatic Cancer</brief_title>
	<detailed_description>During last year , esocrine pancreatic carcinoma present slow constant increase incidence . Chemotherapy determine disappointing result . Gemcitabine determine slight advantage survival clinical benefit comparison gemcitabine cisplatin oxaliplatin Elevated expression EGFR ligand correlate bad prognosis variety human cancer include pancreatic cancer . Therefore , blockade EGFR activity would provide novel strategy treatment cancer . Cetuximab ( C225 ) human/murine chimeric monoclonal antibody direct EGFR bind site . In preclinical setting , Cetuximab demonstrate anticancer activity cell culture experiment `` vivo '' tumor xenograft animal model Since combination gemcitabine cisplatin seem effective treatment advance pancreatic cancer Cetuximab may improve activity combination design phase II randomise trial ass role Cetuximab combination gemcitabine cisplatin pancreatic cancer .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Age ≥ 18 year Histologically confirm diagnosis adenocarcinoma pancreas Locally advance ( nonresectable ) metastatic pancreatic cancer Presence least one unidimensional indicator lesion measurable CT scan MRI irradiate area ( RECIST criterion ) Immunohistochemical evidence positive EGFR expression prior study entry primary tumor and/or least one metastasis Life expectancy ≥ 3 month Karnofsky performance status ≥70 study entry Neutrophils ≥ 1.5 x 109/L , platelet ≥100 x 109/L , hemoglobin ≥ 9 g/dL Bilirubin level either normal &lt; 1.5 x ULN ASAT ALAT ≤ 2.5 X ULN ( ≤ 5 x ULN liver metastasis present ) Serum creatinine &lt; 1.5 x ULN Effective contraception , male female patient risk conception exists Signed write informed consent prior begin protocol specific procedure Brain metastasis Previous chemotherapy locally advance metastatic pancreatic cancer Adjuvant therapy allow recurrence document &gt; 6 month end adjuvant treatment Radiotherapy within 4 week prior study entry Concurrent chronic systemic immune therapy Any investigational agent ( ) 4 week prior entry Previous exposure EGF , monoclonal antibody , signal transduction inhibitor EGFR target therapy Clinically relevant coronary artery disease history myocardial infarction within last 12 month Known grade 3 4 allergic reaction component treatment Known drug abuse/ alcohol abuse Legal incapacity limit legal capacity Medical psychological condition opinion investigator would permit patient complete study sign meaningful inform consent Women pregnant breastfeed Any concurrent malignancy nonmelanoma skin cancer , carcinoma situ cervix . ( Patients previous malignancy without evidence disease ≥ 5 year allow enter trial ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2007</verification_date>
	<keyword>pancreatic cancer</keyword>
	<keyword>metastatic</keyword>
	<keyword>EGFR</keyword>
	<keyword>locally advanced pancreatic cancer</keyword>
</DOC>